AGNPF - Algernon Pharmaceuticals Announces Private Placement | Benzinga
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE:AGN) (FRANKFURT: AGW0) (OTCQB:AGNPF) (the "Company" or "Algernon") a Canadian clinical stage pharmaceutical development company announces a non-brokered private placement for gross proceeds of $250,000 (the "Offering") of units (the "Units") at an issue price of $0.12 per Unit. Each Unit will consist of one Class A common share in the capital of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant"). Each Warrant will entitle the holder to acquire one Common Share (a "Warrant Share") at an exercise price of $0.24 per Warrant Share for a period of 2 years from the date of issuance (the "Expiry Date"), subject to acceleration of the Expiry Date as described below. The Offering is expected to close on July 20, 2024.
The Warrants are subject to accelerated expiry in the event the volume weighted average trading price of the Common Shares exceeds $0.36 for 20 consecutive trading days, the Company may, within 10 business days of the occurrence of such event, deliver a notice to the holders of the Warrants accelerating the Expiry Date of the Warrants to a date that is not less than 30 days following the date of such notice and the issuance of a press release by the Company announcing the acceleration notice (the "Accelerated Exercise Period"). Any unexercised Warrants shall automatically expire at the end of the Accelerated Exercise Period.
The Company may pay cash finder's fees and finders warrants to eligible finders, up to eight percent of the proceeds raised and ...